Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. Nov. 7, 2018. David Boudreau.

Executive Summary

David Boudreau, chair of the committee that oversees the Medical Device Single Audit Program (MDSAP), believes "instability" could come to the device industry if international quality systems standard ISO 13485 is retooled right now. See what he wrote to the International Organization for Standardization (ISO) here.

"If changes are implemented to ISO 13485:2016, the Audit Model for MDSAP, which was just recently revised, will have to be completely revised, training of the auditing organizations will need to be conducted, and transition periods will need to be implemented, leading to instability in the MDSAP at a critical time." –David Boudreau, chair, MDSAP Regulatory Authority Council 

Click here for a free trial of Medtech Insight

 
Advertisement

Related Content

'An Unnecessary Editorial Revision': In Letter, MDSAP Council Rails Against ISO's Push To Change 13485 Quality Standard

Topics

Advertisement
UsernamePublicRestriction

Register

MT124207

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel